Abstract
Neonatal diethylstilbestrol (DES) exposure elicits a wide range of abnormalities in the female mouse genital tract. This animal model system is suitable for investigating the mechanism of DES syndrome in humans. Accumulated evidence has shown that critical periods in development are present for distinct and permanent alterations in the female genital tract of mice exposed to DES neonatally (DES-mice). These effects of DES and other estrogens are mainly mediated by estrogen receptor α (ERα) through multiple pathways. Induction of ERα by DES exposure in neonatal stromal and epithelial cells, and successive premature activation of estrogen-regulated genes are thought to be essential to induce the abnormalities. Induction of malformation, permanent changes in estrogen-regulated genes, such as protooncogenes and growth factors, and carcinogenesis are assumed to be interdependent. This review focuses the following topics to discuss the molecular basis of DES-induced abnormalities mainly based on the results by histochemical techniques in the uterus: spatiotemporal expression of ERa and coactivators, proteins relating morphogenesis, and estrogen-regulated protooncogenes and growth factors.
Keywords: Growth factors, Protooncogenes, Hox, Wnt, Angiogenesis, Estrogen receptors, Female reproductive tract, Diethylstilbestrol
Current Pharmaceutical Design
Title: Expression of Estrogen-Regulated Genes During Development in the Mouse Uterus Exposed to Diethylstilbestrol Neonatally
Volume: 12 Issue: 12
Author(s): Shuji Yamashita
Affiliation:
Keywords: Growth factors, Protooncogenes, Hox, Wnt, Angiogenesis, Estrogen receptors, Female reproductive tract, Diethylstilbestrol
Abstract: Neonatal diethylstilbestrol (DES) exposure elicits a wide range of abnormalities in the female mouse genital tract. This animal model system is suitable for investigating the mechanism of DES syndrome in humans. Accumulated evidence has shown that critical periods in development are present for distinct and permanent alterations in the female genital tract of mice exposed to DES neonatally (DES-mice). These effects of DES and other estrogens are mainly mediated by estrogen receptor α (ERα) through multiple pathways. Induction of ERα by DES exposure in neonatal stromal and epithelial cells, and successive premature activation of estrogen-regulated genes are thought to be essential to induce the abnormalities. Induction of malformation, permanent changes in estrogen-regulated genes, such as protooncogenes and growth factors, and carcinogenesis are assumed to be interdependent. This review focuses the following topics to discuss the molecular basis of DES-induced abnormalities mainly based on the results by histochemical techniques in the uterus: spatiotemporal expression of ERa and coactivators, proteins relating morphogenesis, and estrogen-regulated protooncogenes and growth factors.
Export Options
About this article
Cite this article as:
Yamashita Shuji, Expression of Estrogen-Regulated Genes During Development in the Mouse Uterus Exposed to Diethylstilbestrol Neonatally, Current Pharmaceutical Design 2006; 12 (12) . https://dx.doi.org/10.2174/138161206776389840
DOI https://dx.doi.org/10.2174/138161206776389840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics: The Influence of Genomic Variation on Drug Response
Current Topics in Medicinal Chemistry miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Current Signal Transduction Therapy Transient Production of Recombinant Pharmaceutical Proteins in Plants: Evolution and Perspectives
Current Medicinal Chemistry Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes
Current Topics in Medicinal Chemistry Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets The physics for the formation of cell-in-cell structures.
Current Molecular Medicine Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment
Current Cancer Therapy Reviews Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Gender Specific Drug Metabolism of PF-02341066 in Rats — Role of Sulfoconjugation
Current Drug Metabolism